Antonio J Vallejo-Vaz

List of Publications by Citations

45 papers	1,267 citations	19 h-index	35 g-index
54 ext. papers	1,768 ext. citations	6.5 avg, IF	4.36 L-index

#	Paper	IF	Citations
45	Olive oil polyphenols decrease blood pressure and improve endothelial function in young women with mild hypertension. *American Journal of Hypertension*, **2012**, 25, 1299-304	2.3	138
44	Familial hypercholesterolaemia: A global call to arms. *Atherosclerosis*, **2015**, 243, 257-9	3.1	123
43	Prevalence of Familial Hypercholesterolemia Among the General Population and Patients With Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-Analysis. *Circulation*, **2020**, 141, 1742-1759	16.7	117
42	Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). *Atherosclerosis*, **2018**, 277, 234-255	3.1	93
41	Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up. *Circulation*, **2017**, 136, 1878-1891	16.7	92
40	Reducing the Clinical and Public Health Burden of Familial Hypercholesterolemia: A Global Call to Action. *JAMA Cardiology*, **2020**, 5, 217-229	16.2	85
39	Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial. *Circulation*, **2018**, 138, 770-781	16.7	65
38	Effect of pitavastatin on glucose, HbA1c and incident diabetes: A meta-analysis of randomized controlled clinical trials in individuals without diabetes. *Atherosclerosis*, **2015**, 241, 409-18	3.1	63
37	Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration. *Atherosclerosis Supplements*, **2016**, 22, 1-32	1.7	60
36	Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials. *Atherosclerosis*, **2019**, 288, 194-202	3.1	35
35	Role of the Renin-Angiotensin system and aldosterone on cardiometabolic syndrome. *International Journal of Hypertension*, **2011**, 2011, 685238	2.4	34
34	Role of circulating cell-free DNA levels in patients with severe preeclampsia and HELLP syndrome. *American Journal of Hypertension*, **2013**, 26, 1377-80	2.3	31
33	Obstructive sleep apnea syndrome, vascular pathology, endothelial function and endothelial cells and circulating microparticles. *Archives of Medical Research*, **2013**, 44, 409-14	6.6	27
32	Obstructive sleep apnoea syndrome, endothelial function and markers of endothelialization. Changes after CPAP. *PLoS ONE*, **2015**, 10, e0122091	3.7	25
31	Impact of statin therapy on plasma levels of plasminogen activator inhibitor-1. A systematic review and meta-analysis of randomised controlled trials. *Thrombosis and Haemostasis*, **2016**, 116, 162-71	7	24
30	Which parameter is better to define endothelial dysfunction in a test of postocclusive hyperemia measured by laser-Doppler flowmetry?. *Coronary Artery Disease*, **2012**, 23, 57-61	1.4	24
29	Total and Fetal Circulating Cell-Free DNA, Angiogenic, and Antiangiogenic Factors in Preeclampsia and HELLP Syndrome. *American Journal of Hypertension*, **2017**, 30, 673-682	2.3	21

28	Triglycerides and residual risk. *Current Opinion in Endocrinology, Diabetes and Obesity*, **2020**, 27, 95-103	4	20
27	Epidemiology of familial hypercholesterolaemia: Community and clinical. *Atherosclerosis*, **2018**, 277, 289-297	3.7	19
26	Relation of Fasting Triglyceride-Rich Lipoprotein Cholesterol to Coronary Artery Calcium Score (from the ELSA-Brasil Study). *American Journal of Cardiology*, **2017**, 119, 1352-1358	3	18
25	Fibrate therapy and flow-mediated dilation: A systematic review and meta-analysis of randomized placebo-controlled trials. *Pharmacological Research*, **2016**, 111, 163-179	10.2	17
24	Non-HDL cholesterol goal attainment and its relationship with triglyceride concentrations among diabetic subjects with cardiovascular disease: A nationwide survey of 2674 individuals in Hungary. *Atherosclerosis*, **2015**, 241, 62-8	3.1	14
23	Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). *Lancet, The*, **2021**, 398, 1713-1725	40	14
22	Isolated abducens nerve palsy in preeclampsia and hypertension in pregnancy. *Hypertension Research*, **2013**, 36, 834-5	4.7	13
21	Abnormal levels of antioxidant defenses in a large sample of patients with hypertensive disorders of pregnancy. *Hypertension Research*, **2012**, 35, 274-8	4.7	12
20	The HELLP syndrome (hemolysis, elevated liver enzymes and low platelets): Clinical characteristics and maternal-fetal outcome in 172 patients. *Pregnancy Hypertension*, **2011**, 1, 164-9	2.6	11
19	Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control. *Atherosclerosis*, **2019**, 288, 85-93	3.1	10
18	Maternal body-mass index and cord blood circulating endothelial colony-forming cells. *Journal of Pediatrics*, **2014**, 164, 566-571	3.6	10
17	The evolving role of CETP inhibition: beyond HDL cholesterol. *Lancet, The*, **2015**, 386, 412-4	40	9
16	Familial hypercholesterolemia: is it time to separate monogenic from polygenic familial hypercholesterolemia?. *Current Opinion in Lipidology*, **2020**, 31, 111-118	4.4	8
15	Cholesterol efflux capacity as a novel biomarker for incident cardiovascular events: has high-density lipoprotein been resuscitated?. *Circulation Research*, **2015**, 116, 1646-8	15.7	5
14	Differences in the prevalence of metabolic syndrome and levels of C-reactive protein after puerperium in women with hypertensive disorders during pregnancy. *Hypertension Research*, **2010**, 33, 1012-7	4.7	5
13	A meta-analysis of medications directed against PCSK9 in familial hypercholesterolemia. *Atherosclerosis*, **2021**, 325, 46-56	3.1	5
12	Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study.. *Lancet, The*, **2022**,	40	4
11	Lower On-Treatment Low-Density Lipoprotein Cholesterol and Major Adverse Cardiovascular Events in Women and Men: Pooled Analysis of 10 ODYSSEY Phase 3 Alirocumab Trials. *Journal of the American Heart Association*, **2018**, 7, e009221	6	4

10	Novel Biomarkers in Heart Failure Beyond Natriuretic Peptides - The Case for Soluble ST2. *European Cardiology Review*, **2015**, 10, 37-41	3.9	3
9	Effect of computerised, knowledge-based, clinical decision support systems on patient-reported and clinical outcomes of patients with chronic disease managed in primary care settings: a systematic review.. *BMJ Open*, **2021**, 11, e054659	3	2
8	Triglyceride concentrations and non-high-density lipoprotein cholesterol goal attainment in the ODYSSEY phase 3 trials with alirocumab. *European Journal of Preventive Cardiology*, **2020**, 27, 1663-1674	3.9	1
7	The Postprandial State and its Influence on the Development of Atherosclerosis. *Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry*, **2011**, 11, 1-9		1
6	Cerebrovascular Disease and Statins.. *Frontiers in Cardiovascular Medicine*, **2021**, 8, 778740	5.4	1
5	LDL-cholesterol lowering and clinical outcomes in hypercholesterolemic subjects with and without a familial hypercholesterolemia phenotype: Analysis from the secondary prevention 4S trial. *Atherosclerosis*, **2021**, 320, 1-9	3.1	1
4	Response by Vallejo-Vaz et al to Letters Regarding Article, "Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year	16.7	0
3	Prevalence of familial hypercholesterolemia phenotype and ten-year risk of cardiovascular events in a working population in primary prevention: The ICARIA study. *Atherosclerosis*, **2021**, 338, 39-45	3.1	0
2	Coexistence of two causes of secondary hypertension in a single patient. *Revista Clinica Espanola*, **2013**, 213, e81-e83	0.7	
1	: Reducing Risk in Familial Hypercholesterolaemia and Severe Dyslipidaemia: Novel Drugs Targeting PCSK9. *European Cardiology Review*, **2018**, 13, 7-8	3.9	